Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
作者机构：Department of Thoracic SurgeryTangdu HospitalThe Air Force Military Medical UniversityXi'anShaanxi 710038China Department of Medical OncologySenior Department of OncologyThe Fifth Medical Center of PLA General HospitalBeijing 100853China Department of UrologyThe First Affiliated Hospital of Xi'an Jiaotong UniversityXi'anShaanxi 710061China Department of OphthalmologyTangdu HospitalThe Air Force Medical UniversityXi'anShaanxi 710038China
出 版 物：《Genes & Diseases》 (基因与疾病（英文）)
年 卷 期：2023年第10卷第3期
页 面：848-863页
核心收录：
学科分类：0710[理学-生物学] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by the National Natural Science Foundation of China(82103508,81871866,82173252) Shaanxi Special Support Plan-Program for Leading Talents of Science and Technology Innovation(China)(No.2019 Special Support Plan) the Natural Science Foundation of Shaanxi Province(China)(2016SF-308,2019SF-033,2022SF-145) Project of Tangdu Hospital,the Fourth Military Medical University(China)(No.2018 Key Talents).
主 题：Cancer Deubiquitination Immunotherapy PD-1 PD-L1 Ubiquitination
摘 要：As members of the immune checkpoint family, PD-1 and its ligand PD-L1 play critical roles in maintaining the balance between autoimmunity and tolerance. The interaction of PD-1/PD-L1 is also involved in tumor evasion inside the tumor microenvironment, caused by reduced T cell activation, proliferation, cytotoxic secretion, and survival. Previous research has shown that the expression level of PD-1/PD-L1 may be regulated by ubiquitin-mediated proteasome degradation, which is an important mode of post-translational modification (PTM). PD-1/PD-L1 ubiquitin modification research in tumor immunotherapy is the subject of the present review, which aims to assess the most recent developments in this area. We offer a short explanation of PD-1/PD-L1 as well as some basic background information on the UPS system and discuss many routes that target E3s and DUBs, respectively, in the regulation of PD-1/PD-L1 in tumor immunotherapy. In addition, we offer numerous innovative prospective research areas for the future, as well as novel immunotherapy concepts and ideas. Taken together, the information compiled herein should serve as a comprehensive repository of information about tumor immunotherapy that is currently available, and it should be useful in the design of future studies, as well as the development of potential targets and strategies for future tumor immunotherapy.
维普期刊数据库